SOPHiA GENETICS (SOPH) Liabilities and Shareholders Equity (2020 - 2026)

SOPHiA GENETICS has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $163.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 4.97% year-over-year to $163.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $650.8 million (down 6.26% YoY) and the FY2025 annual result came in at $163.0 million, up 4.97% from the prior year.
• Liabilities and Shareholders Equity steadied at $163.0 million in Q4 2025 per SOPH's latest filing, from $163.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $334.9 million in Q3 2021 and troughed at $104.0 million in Q2 2021.
• A 5-year average of $212.7 million and a median of $205.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 166.45% in 2022, down 25.18% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $320.2 million in 2021, then retreated by 23.84% to $243.8 million in 2022, then declined by 15.45% to $206.2 million in 2023, then slipped by 24.66% to $155.3 million in 2024, then climbed by 4.97% to $163.0 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $163.0 million, $163.5 million, and $177.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.